German pharmaceutical company Sygnis Pharma said today that it is acquiring X-Pol Biotech, a subsidiary of Spanish biotechnology holding company Genetrix, in a bid to further develop and market X-Pol's DNA sequencing technologies and products, including its DNA polymerase technology.

News of the acquisition follows an announcement earlier this week that X-Pol had inked an exclusive, worldwide licensing deal with Qiagen for the polymerase, called Qualiphi.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.